The tumor microenvironment and dendritic cells: Developers of pioneering strategies in colorectal cancer immunotherapy?

被引：2
作者：
Ghorbaninezhad, Farid [1 ,2 ]
Nour, Mina Afrashteh [3 ]
Farzam, Omid Rahbar [3 ]
Saeedi, Hossein [3 ]
Vanan, Ahmad Ghorbani [1 ,2 ]
Bakhshivand, Mohammad [3 ,4 ]
Jafarlou, Mahdi [2 ,3 ]
Hatami-sadr, Amirhossein [5 ]
Baradaran, Behzad [2 ,3 ,4 ]
机构：
[1] Shahid Beheshti Univ Med Sci, Student Res Comm, Sch Med, Dept Immunol, Tehran, Iran
[2] Ardabil Univ Med Sci, Canc Immunol & Immunotherapy Res Ctr, Ardebil, Iran
[3] Tabriz Univ Med Sci, Immunol Res Ctr, Daneshghah Ave, Tabriz, Iran
[4] Tabriz Univ Med Sci, Fac Med, Dept Immunol, Tabriz, Iran
[5] Tabriz Univ Med Sci, Fac Dent, Tabriz, Iran
来源：
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2025年 / 1880卷 / 02期
关键词：
DCs; TME; Colorectal cancer; TME-related DC deficiency; DC-based cell therapy; T-CELLS; COLON-CANCER; RANDOMIZED-TRIAL; POTENT ANTITUMOR; PROGNOSTIC VALUE; MESSENGER-RNA; KILLER-CELLS; PHASE-II; ANTIGEN; ACTIVATION;
D O I：
10.1016/j.bbcan.2025.189281
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Colorectal cancer (CRC) is the world's third most frequent cancer, and both its incidence and fatality rates are rising. Despite various therapeutic approaches, neither its mortality rate nor its recurrence frequency has decreased significantly. Additionally, conventional treatment approaches, such as chemotherapy and radiotherapy, have several side effects and risks for patients with CRC. Accordingly, the need for alternative and effective treatments for CRC patients is critical. Immunotherapy that utilizes dendritic cells (DCs) harnesses the patient's immune system to combat cancer cells effectively. DCs are the most potent antigen-presenting cells (APCs), which play a vital role in generating anti-cancer T cell responses. A significant barrier to the immune system's ability to eliminate CRC is the establishment of a potent immunosuppressive tumor milieu by malignant cells. Since DCs are frequently defective in this milieu, the tumor setting significantly reduces the effectiveness of DC-based therapy. Determining central mechanisms contributing to tumor growth by unraveling and comprehending the interaction between CRC tumor milieu and DCs may lead to new therapeutic approaches. This study aims to review DC biology and discuss its role in T-cell-mediated anti-tumor immunity, as well as to highlight the immunosuppressive effects of the CRC tumor milieu on the function of DCs. We will also highlight the tumor microenvironment (TME)-related factors that interfere with DC function as a possible therapeutic target to enhance DC-based cell therapy efficacy.
引用
收藏
页数：20
相关论文
共 163 条
  • [1] Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Et al., Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 71, 3, pp. 209-249, (2021)
  • [2] Wang J., Li S., Liu Y., Zhang C., Li H., Lai B., Metastatic patterns and survival outcomes in patients with stage IV colon cancer: a population-based analysis, Cancer Med., 9, 1, pp. 361-373, (2020)
  • [3] Yoshino T., Arnold D., Taniguchi H., Pentheroudakis G., Yamazaki K., Xu R.H., Et al., Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS, Ann. Oncol., 29, 1, pp. 44-70, (2018)
  • [4] Gootjes E.C., van der Stok E.P., Buffart T.E., Bakkerus L., Labots M., Zonderhuis B.M., Et al., Safety and feasibility of additional tumor Debulking to first-line palliative combination chemotherapy for patients with multiorgan metastatic colorectal Cancer, Oncologist, 25, 8, pp. e1195-e1201, (2020)
  • [5] Venook A.P., Niedzwiecki D., Lenz H.J., Innocenti F., Fruth B., Meyerhardt J.A., Et al., Effect of first-line chemotherapy combined with Cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial, JAMA, 317, 23, pp. 2392-2401, (2017)
  • [6] Cornista A.M., Giolito M.V., Baker K., Hazime H., Dufait I., Datta J., Et al., Colorectal Cancer immunotherapy: state of the art and future directions, Gastro Hep. Adv., 2, 8, pp. 1103-1119, (2023)
  • [7] Miyamoto Y., Ogawa K., Ohuchi M., Tokunaga R., Baba H., Emerging evidence of immunotherapy for colorectal cancer, Ann. Gastroenterol. Surg., 7, 2, pp. 216-224, (2023)
  • [8] Ghazi B., El Ghanmi A., Kandoussi S., Ghouzlani A., Badou A., CAR T-cells for colorectal cancer immunotherapy: ready to go?, Front. Immunol., 13, (2022)
  • [9] Huyghe N., Benidovskaya E., Stevens P., Van den Eynde M., Biomarkers of response and resistance to immunotherapy in microsatellite stable colorectal cancer: toward a new personalized medicine, Cancers (Basel), 14, 9, (2022)
  • [10] Li Y., Zheng Y., Liu T., Liao C., Shen G., He Z., The potential and promise for clinical application of adoptive T cell therapy in cancer, J. Transl. Med., 22, 1, (2024)
12345678910